Shen C, Wang Z, Fang Z, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 2020;323:1582–9.ShenCWangZFangZTreatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA2020;323:1582–9.10.1001/jama.2020.4783710150732219428Search in Google Scholar
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020; 20:398–400.ChenLXiongJBaoLShiY. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis2020; 20:398–400.10.1016/S1473-3099(20)30141-9712821832113510Search in Google Scholar
Rodriguez Z, Shane AL, Verkerke H, et al. COVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease. Blood Adv 2020;4:4278–81.RodriguezZShaneALVerkerkeHCOVID-19 convalescent plasma clears SARS-CoV-2 refractory to remdesivir in an infant with congenital heart disease. Blood Adv2020;4:4278–81.10.1182/bloodadvances.2020002507750985832915971Search in Google Scholar
Joyner MJ, Wright RS, Fairweather D, et al. Early safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest 2020;130:4791–7.JoynerMJWrightRSFairweatherDEarly safety indicators of COVID-19 convalescent plasma in 5000 patients. J Clin Invest2020;130:4791–7.10.1172/JCI140200745623832525844Search in Google Scholar
Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest 2020;158:e9–e13.ZhangBLiuSTanTTreatment with convalescent plasma for critically ill patients with severe acute respiratory syndrome coronavirus 2 infection. Chest2020;158:e9–e13.10.1016/j.chest.2020.03.039719533532243945Search in Google Scholar
Joyner MJ, Carter RE, Senefeld JW, et al. Convalescent plasma antibody levels and the risk of death from COVID-19. N Engl J Med. 13 January 2021 [Epub ahead of print]. DOI: 10.1056/NEJMoa2031893. Available from https://pubmed.ncbi.nlm.nih.gov/33523609/. Accessed January 2021.JoynerMJCarterRESenefeldJWConvalescent plasma antibody levels and the risk of death from COVID-19. N Engl J Med.13 January 2021 [Epub ahead of print]. DOI: 10.1056/NEJMoa2031893. Available fromhttps://pubmed.ncbi.nlm.nih.gov/33523609/. Accessed January 2021.Search in Google Scholar
Libster R, Marc GP, Wappner D, et al. Early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med 2021;384:610–8.LibsterRMarcGPWappnerDEarly high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med2021;384:610–8.10.1056/NEJMoa2033700779360833406353Search in Google Scholar
Stowell SR, Guarner J. Role of serology in the coronavirus disease 2019 pandemic. Clin Infect Dis 2020;71:1935–6.StowellSRGuarnerJ. Role of serology in the coronavirus disease 2019 pandemic. Clin Infect Dis2020;71:1935–6.10.1093/cid/ciaa510719761832357206Search in Google Scholar
den Hartog G, Schepp RM, Kuijer M, et al. SARS-CoV-2-specific antibody detection for seroepidemiology: a multiplex analysis approach accounting for accurate seroprevalence. J Infect Dis 2020;222:1452–61.den HartogGScheppRMKuijerMSARS-CoV-2-specific antibody detection for seroepidemiology: a multiplex analysis approach accounting for accurate seroprevalence. J Infect Dis2020;222:1452–61.10.1093/infdis/jiaa479745474032766833Search in Google Scholar
Lan J, Ge J, Yu J, et al. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 2020;581:215–20.LanJGeJYuJStructure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature2020;581:215–20.10.1038/s41586-020-2180-532225176Search in Google Scholar
Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science 2020;368:630–3.YuanMWuNCZhuXA highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science2020;368:630–3.10.1126/science.abb7269716439132245784Search in Google Scholar
Verkerke H, Horwath M, Saeedi B, et al. Comparison of antibody class specific SARS-CoV-2 serology for the diagnosis of acute COVID-19. J Clin Microbiol. 10 January 2021 [Epub ahead of print]. DOI: 10.1128/JCM.02026-20. Available from https://pubmed.ncbi.nlm.nih.gov/33468605/. Accessed January 2021.VerkerkeHHorwathMSaeediBComparison of antibody class specific SARS-CoV-2 serology for the diagnosis of acute COVID-19. J Clin Microbiol.10 January 2021 [Epub ahead of print]. DOI: 10.1128/JCM.02026-20. Available fromhttps://pubmed.ncbi.nlm.nih.gov/33468605/. Accessed January 2021.10.1128/JCM.02026-20809274133468605Search in Google Scholar
Allen JWL, Verkerke H, Owens J, et al. Serum pooling for rapid expansion of anti-SARS-CoV-2 antibody testing capacity. Transfus Clin Biol 2021;28:51–4.AllenJWLVerkerkeHOwensJSerum pooling for rapid expansion of anti-SARS-CoV-2 antibody testing capacity. Transfus Clin Biol2021;28:51–4.10.1016/j.tracli.2020.10.008757542533096207Search in Google Scholar
Suthar MS, Zimmerman MG, Kauffman RC, et al. Rapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med 2020;1:100040.SutharMSZimmermanMGKauffmanRCRapid generation of neutralizing antibody responses in COVID-19 patients. Cell Rep Med2020;1:100040.10.1016/j.xcrm.2020.100040727630232835303Search in Google Scholar
Luchsinger LL, Ransegnola B, Jin D, et al. Serological analysis of New York City COVID19 convalescent plasma donors. medRxiv 2020 June 9;2020.06.08.20124792.LuchsingerLLRansegnolaBJinDSerological analysis of New York City COVID19 convalescent plasma donors. medRxiv 2020 June 9;2020.06.08.20124792.Search in Google Scholar
Corthesy B. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol 2013;4:185.CorthesyB. Multi-faceted functions of secretory IgA at mucosal surfaces. Front Immunol2013;4:185.10.3389/fimmu.2013.00185370941223874333Search in Google Scholar
Frey A, Di Canzio J, Zurakowski D. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods 1998;221: 35–41.FreyADi CanzioJZurakowskiD. A statistically defined endpoint titer determination method for immunoassays. J Immunol Methods1998;221: 35–41.10.1016/S0022-1759(98)00170-79894896Search in Google Scholar
Ramakrishnan MA. Determination of 50% endpoint titer using a simple formula. World J Virol 2016;5:85–6.RamakrishnanMA. Determination of 50% endpoint titer using a simple formula. World J Virol2016;5:85–6.10.5501/wjv.v5.i2.85486187527175354Search in Google Scholar
Spackman E, Malladi S, Ssematimba A, Stephens CB. Assessment of replicate numbers for titrating avian influenza virus using dose-response models. J Vet Diagn Invest 2019;31:616–9.SpackmanEMalladiSSsematimbaAStephensCB. Assessment of replicate numbers for titrating avian influenza virus using dose-response models. J Vet Diagn Invest2019;31:616–9.10.1177/1040638719853851685702231131714Search in Google Scholar
Stowe RP, Ruiz RJ, Fagundes CP, Stowe RH, Chen M, Glaser R. An ELISA method to compute endpoint titers to Epstein-Barr virus and cytomegalovirus: application to population-based studies. J Immunol Methods 2014;408:64–9.StoweRPRuizRJFagundesCPStoweRHChenMGlaserR. An ELISA method to compute endpoint titers to Epstein-Barr virus and cytomegalovirus: application to population-based studies. J Immunol Methods2014;408:64–9.10.1016/j.jim.2014.05.006409811624859346Search in Google Scholar
Balingit JC, Ly MHP, Matsuda M, et al. A simple and high-throughput ELISA-based neutralization assay for the determination of anti-flavivirus neutralizing antibodies. Vaccines (Basel) 2020;8:297.BalingitJCLyMHPMatsudaMA simple and high-throughput ELISA-based neutralization assay for the determination of anti-flavivirus neutralizing antibodies. Vaccines (Basel)2020;8:297.10.3390/vaccines8020297735001532532141Search in Google Scholar
Pujadas E, Ibeh N, Hernandez MM, et al. Comparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test. J Med Virol 2020;92: 1695–8.PujadasEIbehNHernandezMMComparison of SARS-CoV-2 detection from nasopharyngeal swab samples by the Roche cobas 6800 SARS-CoV-2 test and a laboratory-developed real-time RT-PCR test. J Med Virol2020;92: 1695–8.10.1002/jmv.25988726754632383179Search in Google Scholar
Xu P, Sun GD, Li ZZ. Clinical characteristics of two human-to-human transmitted coronaviruses: corona virus disease 2019 vs. Middle East respiratory syndrome coronavirus. Eur Rev Med Pharmacol Sci 2020;24:5797–809.XuPSunGDLiZZ. Clinical characteristics of two human-to-human transmitted coronaviruses: corona virus disease 2019 vs. Middle East respiratory syndrome coronavirus. Eur Rev Med Pharmacol Sci2020;24:5797–809.Search in Google Scholar
Huang JL, Lin HT, Wang YM, et al. Rapid and sensitive detection of multiple genes from the SARS-coronavirus using quantitative RT-PCR with dual systems. J Med Virol 2005;77:151–8.HuangJLLinHTWangYMRapid and sensitive detection of multiple genes from the SARS-coronavirus using quantitative RT-PCR with dual systems. J Med Virol2005;77:151–8.10.1002/jmv.20432716650216121372Search in Google Scholar
GraphPad Prism 8. 2020. Available from https://www.graphpad.com/scientific-software/prism/. Accessed 2020.GraphPadPrismGraphPad Prism 8GraphPad Prism8.2020.Available fromhttps://www.graphpad.com/scientific-software/prism/. Accessed 2020.Search in Google Scholar
Kohn LT, Corrigan JM, Donaldson MS, Eds. To Err is Human: Building a Safer Health System. Washington, DC: National Academic Press, 2000.KohnLTCorriganJMDonaldsonMS, Eds. To Err is Human: Building a Safer Health System. Washington, DC: National Academic Press, 2000.Search in Google Scholar
Python 3.0 Release. 2020. Available from https://www.python.org/download/releases/3.0. Accessed 2020.Python 3.0 ReleasePython 3.0. 2020. Available fromhttps://www.python.org/download/releases/3.0. Accessed 2020.Search in Google Scholar
Roback JD, Guarner J. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA 2020;323:1561–2.RobackJDGuarnerJ. Convalescent plasma to treat COVID-19: possibilities and challenges. JAMA2020;323:1561–2.10.1001/jama.2020.494032219429Search in Google Scholar
Gharbharan A, Jordans CCE, Geurtsvankessel C, et al. Convalescent plasma for COVID-19; A randomized clinical trial. medRxiv 2020.07.01.20139857.GharbharanAJordansCCEGeurtsvankesselCConvalescent plasma for COVID-19; A randomized clinical trial. medRxiv2020.07.01.20139857.Search in Google Scholar
Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ 2020;371:m3939.AgarwalAMukherjeeAKumarGConvalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial). BMJ2020;371:m3939.10.1136/bmj.m3939757866233093056Search in Google Scholar
Eckhardt CM, Cummings MJ, Rajagopalan KN, et al. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials 2020;21:499.EckhardtCMCummingsMJRajagopalanKNEvaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: a structured summary of a study protocol for a randomized controlled trial. Trials2020;21:499.10.1186/s13063-020-04422-y727697432513308Search in Google Scholar
Zerra PE, Cox C, Baldwin WH, et al. Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A. Blood 2017;130:2559–68.ZerraPECoxCBaldwinWHMarginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A. Blood2017;130:2559–68.10.1182/blood-2017-05-782912572128228978569Search in Google Scholar
Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. Hematology Am Soc Hematol Educ Program 2014;2014:364–71.KemptonCLMeeksSL. Toward optimal therapy for inhibitors in hemophilia. Hematology Am Soc Hematol Educ Program2014;2014:364–71.10.1182/asheducation-2014.1.36425696880Search in Google Scholar
Strandenes G, Berséus O, Cap AP, et al. Low titer group O whole blood in emergency situations. Shock 2014;41(Suppl 1):70–5.StrandenesGBerséusOCapAPLow titer group O whole blood in emergency situations. Shock2014;41(Suppl 1):70–5.10.1097/SHK.000000000000015024569505Search in Google Scholar
Stowell SR, Stowell CP. Biologic roles of the ABH and Lewis histo-blood group antigens part II: thrombosis, cardiovascular disease and metabolism. Vox Sang 2019;114:426–42.StowellSRStowellCP. Biologic roles of the ABH and Lewis histo-blood group antigens part II: thrombosis, cardiovascular disease and metabolism. Vox Sang2019;114:426–42.10.1111/vox.1278731070258Search in Google Scholar
Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest 2020;130:2757–65.BlochEMShohamSCasadevallADeployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest2020;130:2757–65.10.1172/JCI138745725998832254064Search in Google Scholar
Denomme GA, Anani WQ. ABO titers: harmonization and identifying clinically relevant ABO antibodies. Transfusion 2020;60:441–3.DenommeGAAnaniWQ. ABO titers: harmonization and identifying clinically relevant ABO antibodies. Transfusion2020;60:441–3.10.1111/trf.1572632128831Search in Google Scholar
Adcock DM, Favaloro EJ. Pearls and pitfalls in factor inhibitor assays. Int J Lab Hematol 2015;37(Suppl 1):52–60.AdcockDMFavaloroEJ. Pearls and pitfalls in factor inhibitor assays. Int J Lab Hematol2015;37(Suppl 1):52–60.10.1111/ijlh.1235225976961Search in Google Scholar
Katz LM. (A little) clarity on convalescent plasma for Covid-19. N Engl J Med 2021;384:666–8.KatzLM. (A little) clarity on convalescent plasma for Covid-19. N Engl J Med2021;384:666–8.10.1056/NEJMe2035678782198233440086Search in Google Scholar
Verkerke HP, Maier CL. Towards characterized convalescent plasma for COVID-19: the dose matters. EClinicalMedicine 2020;26:100545.VerkerkeHPMaierCL. Towards characterized convalescent plasma for COVID-19: the dose matters. EClinicalMedicine2020;26:100545.10.1016/j.eclinm.2020.100545750152632984783Search in Google Scholar
Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict disease severity and survival. Cell 2021;184:476–488.e11.Garcia-BeltranWFLamECAstudilloMGCOVID-19-neutralizing antibodies predict disease severity and survival. Cell2021;184:476–488.e11.10.1016/j.cell.2020.12.015783711433412089Search in Google Scholar
Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020;324:460–70.LiLZhangWHuYEffect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA2020;324:460–70.10.1001/jama.2020.10044727088332492084Search in Google Scholar
Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021;384:693–704.HorbyPLimWSEmbersonJRDexamethasone in hospitalized patients with Covid-19. N Engl J Med2021;384:693–704.10.1056/NEJMoa2021436738359532678530Search in Google Scholar
Woodruff MC, Ramonell RP, Lee FE, Sanz I. Broadly-targeted autoreactivity is common in severe SARS-CoV-2 infection. medRxiv 2020 Oct 23;2020.10.21.20216192.WoodruffMCRamonellRPLeeFESanzI. Broadly-targeted autoreactivity is common in severe SARS-CoV-2 infection. medRxiv 2020 Oct 23;2020.10.21.20216192.Search in Google Scholar
Devreese KMJ, Linskens EA, Benoi D, Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: a relevant observation? J Thromb Haemost 2020;18:2191–2201.DevreeseKMJLinskensEABenoiDPeperstraeteH. Antiphospholipid antibodies in patients with COVID-19: a relevant observation?J Thromb Haemost2020;18:2191–2201.10.1111/jth.14994736125332619328Search in Google Scholar
Khamsi R. Rogue antibodies could be driving severe COVID-19. Nature 2021;590:29–31.KhamsiR. Rogue antibodies could be driving severe COVID-19. Nature2021;590:29–31.10.1038/d41586-021-00149-133469204Search in Google Scholar
Holst LB, Haase N, Wetterslev J, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med 2014;371:1381–91.HolstLBHaaseNWetterslevJLower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med2014;371:1381–91.10.1056/NEJMoa140661725270275Search in Google Scholar
Sparger KA, Assmann SF, Granger S, et al. Platelet transfusion practices among very-low-birth-weight infants. JAMA Pediatr 2016;170:687–94.SpargerKAAssmannSFGrangerSPlatelet transfusion practices among very-low-birth-weight infants. JAMA Pediatr2016;170:687–94.10.1001/jamapediatrics.2016.0507637727927213618Search in Google Scholar
Curley A, Stanworth SJ, Willoughby K, et al. Randomized trial of platelet-transfusion thresholds in neonates. N Engl J Med 2019;380:242–51.CurleyAStanworthSJWilloughbyKRandomized trial of platelet-transfusion thresholds in neonates. N Engl J Med2019;380:242–51.10.1056/NEJMoa180732030387697Search in Google Scholar
Chou ST, Alsawas M, Fasano RM, et al. American Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv 2020;4:327–55.ChouSTAlsawasMFasanoRMAmerican Society of Hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv2020;4:327–55.10.1182/bloodadvances.2019001143698839231985807Search in Google Scholar
Thein SL, Pirenne F, Fasano RM, et al. Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal. Haematologica 2020;105:539–44.TheinSLPirenneFFasanoRMHemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal. Haematologica2020;105:539–44.10.3324/haematol.2019.224709704933032029505Search in Google Scholar
Cohn CS. Platelet transfusion refractoriness: how do I diagnose and manage? Hematology Am Soc Hematol Educ Program 2020;2020:527–32.CohnCS. Platelet transfusion refractoriness: how do I diagnose and manage?Hematology Am Soc Hematol Educ Program2020;2020:527–32.10.1182/hematology.2020000137772758433275694Search in Google Scholar
Arthur CM, Patel SR, Sullivan HC, et al. CD8+ T cells mediate antibody-independent platelet clearance in mice. Blood 2016;127:1823–7.ArthurCMPatelSRSullivanHCCD8+ T cells mediate antibody-independent platelet clearance in mice. Blood2016;127:1823–7.10.1182/blood-2015-10-673426482541526787734Search in Google Scholar
Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv 2020 Aug 12;2020.08.12.20169359.JoynerMJSenefeldJWKlassenSAEffect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv 2020 Aug 12;2020.08.12.20169359.10.1101/2020.08.12.20169359743062332817978Search in Google Scholar
Ezzelle J, Rodriguez-Chavez IR, Darden JM, et al. Guidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. J Pharm Biomed Anal 2008;46:18–29.EzzelleJRodriguez-ChavezIRDardenJMGuidelines on good clinical laboratory practice: bridging operations between research and clinical research laboratories. J Pharm Biomed Anal2008;46:18–29.10.1016/j.jpba.2007.10.010221390618037599Search in Google Scholar
Kubina R, Dziedzic A. Molecular and serological tests for COVID-19: a comparative review of SARS-CoV-2 coronavirus laboratory and point-of-care diagnostics. Diagnostics (Basel) 2020;10:434.KubinaRDziedzicA. Molecular and serological tests for COVID-19: a comparative review of SARS-CoV-2 coronavirus laboratory and point-of-care diagnostics. Diagnostics (Basel)2020;10:434.10.3390/diagnostics10060434734521132604919Search in Google Scholar
Lisboa Bastos M, Tavaziva G, Kunal Abidi S, et al. Diagnostic accuracy of serological tests for COVID-19: systematic review and meta-analysis. BMJ 2020;370:m2516.Lisboa BastosMTavazivaGKunal AbidiSDiagnostic accuracy of serological tests for COVID-19: systematic review and meta-analysis. BMJ2020;370:m2516.10.1136/bmj.m2516732791332611558Search in Google Scholar
